Throne Science: Passive Health Monitoring in the Bathroom
Read about how Throne Science is advancing passive health monitoring with AI-powered sensing that automatically captures daily toilet habit data.
HealthTech & AI
Discover how artificial intelligence and healthtech are transforming healthcare and drug development.
How Should Pharma Companies Audit AI Vendors?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
AI Creates New Viruses? Not Quite. AI-Designed Bacteriophages
AI-designed bacteriophages show how genome models could create new antibacterial therapies while forcing pharma to rethink biological AI governance and biosecurity.
WHOOP x Natural Cycles: Wearable Health Data x Women’s Health
WHOOP and Natural Cycles show how wearable health data is moving into regulated digital health, creating new opportunities for women’s health and pharma.
RNA Biosensors for Real-Time Diabetes Detection and Monitoring
RNA biosensors for diabetes could allow earlier diagnosis and better personalised care. Explore the power of AI monitoring and next-generation molecular diagnostics.
Google SensorFM: One Trillion Minutes of Wearable AI Data
Google SensorFM was pretrained on over one trillion minutes of wearable data. Discover what this AI foundation model could mean for digital health and pharma.
Anthropic’s Gates Foundation Partnership and Healthcare AI
See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Foundational AI In Cell and Gene Therapy Development Success
Discover why AI in cell and gene therapy is necessary for successful development by improving drug discovery, viral vector engineering, manufacturing, and quality control.
Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
Claude Science: An Operating System for AI-Driven Pharma R&D
Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.
AI and Neuroscience. Why Big Pharma Is Betting on the Brain
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
